Oxurion NV (OXUR.BR)
EUR 0.27
(0.0%)
EUR 0.27
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 12.33 Million EUR | 53.87% |
| 2022 | 8.01 Million EUR | -33.75% |
| 2021 | 12.09 Million EUR | 1003.92% |
| 2020 | 1.09 Million EUR | -50.92% |
| 2019 | 2.23 Million EUR | 0.0% |
| 2018 | - EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| 2016 | - EUR | 0.0% |
| 2015 | - EUR | 0.0% |
| 2014 | - EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| 2011 | - EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 11.67 Million EUR | 0.0% |
| 2023 FY | 12.33 Million EUR | 53.87% |
| 2023 Q4 | 12.33 Million EUR | 0.0% |
| 2023 Q2 | 10.95 Million EUR | 0.0% |
| 2022 Q4 | 8.01 Million EUR | 0.0% |
| 2022 Q2 | 8.1 Million EUR | 0.0% |
| 2022 FY | 8.01 Million EUR | -33.75% |
| 2021 FY | 12.09 Million EUR | 1003.92% |
| 2021 Q2 | 735 Thousand EUR | 0.0% |
| 2021 Q4 | 12.09 Million EUR | 0.0% |
| 2020 Q4 | 1.09 Million EUR | 0.0% |
| 2020 Q2 | 1.8 Million EUR | 0.0% |
| 2020 FY | 1.09 Million EUR | -50.92% |
| 2019 Q2 | 2.46 Million EUR | 0.0% |
| 2019 FY | 2.23 Million EUR | 0.0% |
| 2019 Q4 | 2.23 Million EUR | 0.0% |
| 2018 Q4 | - EUR | 0.0% |
| 2018 FY | - EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2017 Q2 | - EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| 2017 Q4 | - EUR | 0.0% |
| 2016 FY | - EUR | 0.0% |
| 2016 Q4 | - EUR | 0.0% |
| 2016 Q2 | - EUR | 0.0% |
| 2015 Q2 | - EUR | 0.0% |
| 2015 FY | - EUR | 0.0% |
| 2015 Q4 | - EUR | 0.0% |
| 2014 Q2 | - EUR | 0.0% |
| 2014 FY | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2013 Q2 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2013 Q4 | - EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q4 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -263.835% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 77.762% |
| Adocia SA | 13.08 Million EUR | 5.761% |
| Aelis Farma SA | 4.03 Million EUR | -205.448% |
| Biophytis S.A. | 8.27 Million EUR | -49.141% |
| Advicenne S.A. | 17.42 Million EUR | 29.217% |
| genOway Société anonyme | 7.23 Million EUR | -70.514% |
| IntegraGen SA | 1.12 Million EUR | -996.614% |
| Medesis Pharma S.A. | 1.2 Million EUR | -927.833% |
| Neovacs S.A. | 650 Thousand EUR | -1797.538% |
| NFL Biosciences SA | 62.17 Thousand EUR | -19737.874% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -183.117% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -353.983% |
| Sensorion SA | 2.86 Million EUR | -329.938% |
| Theranexus Société Anonyme | 3.64 Million EUR | -238.565% |
| TME Pharma N.V. | 1.16 Million EUR | -957.804% |
| Valbiotis SA | 6.87 Million EUR | -79.325% |
| TheraVet SA | 1.15 Million EUR | -963.398% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -37.075% |
| argenx SE | 18.1 Million EUR | 31.876% |
| BioSenic S.A. | 28.16 Million EUR | 56.202% |
| Celyad Oncology SA | 902 Thousand EUR | -1267.406% |
| DBV Technologies S.A. | 13.01 Million USD | 5.259% |
| Galapagos NV | 9.59 Million EUR | -28.533% |
| Genfit S.A. | 70.17 Million EUR | 82.425% |
| GeNeuro SA | 7.73 Million EUR | -59.399% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -132.981% |
| Innate Pharma S.A. | 39.89 Million EUR | 69.082% |
| Inventiva S.A. | 37.4 Million EUR | 67.028% |
| MaaT Pharma SA | 14.07 Million EUR | 12.369% |
| MedinCell S.A. | 58.96 Million EUR | 79.081% |
| Nanobiotix S.A. | 50.56 Million EUR | 75.608% |
| Onward Medical N.V. | 16.87 Million EUR | 26.905% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 9.887% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 73.07% |
| Pharming Group N.V. | 155.29 Million EUR | 92.058% |
| Poxel S.A. | 46.9 Million EUR | 73.701% |
| GenSight Biologics S.A. | 18.42 Million EUR | 33.069% |
| Transgene SA | 1.25 Million EUR | -881.225% |
| Financière de Tubize SA | 79.2 Million EUR | 84.427% |
| UCB SA | 3.03 Billion EUR | 99.594% |
| Valneva SE | 208.81 Million EUR | 94.093% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -32357.895% |